User:Mr. Ibrahem/Palivizumab

Palivizumab, sold under the brand name Synagis, is a medication used to prevent severe respiratory syncytial virus (RSV) infections in those at high risk. This includes those under 6 months who were born premature and those under two years with certain heart or lung diseases. It is given once a month by intramuscular (IM) injection, during the RSV season.

The most common side effects are fever and rash. Severe side effects may include anaphylaxis and low platelets. It is not used in adults. It is a monoclonal antibody directed against fusion protein A of RSV, blocking its entry into cells of the lungs.

Palivizumab was approved for medical use in the United States in 1998 and Europe in 1999. In Canada it costs about 7,000 CAD per year in 2017. In the the United Kingdome it costs about £560 and in the United States it costs about 3,200 USD for 100 mg as of 2021.